Intervacc AB (publ) (STO:IVACC)

Market Cap	389.21M +30.1%
Revenue (ttm)	20.09M +70.4%
Net Income	-80.82M
EPS	-0.27
Shares Out	340.81M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	149,183
Average Volume	501,849
Open	1.142
Previous Close	1.150
Day's Range	1.126 - 1.164
52-Week Range	0.572 - 1.352
Beta	-0.07
RSI	64.74
Earnings Date	Apr 14, 2026

About Intervacc AB

Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company’s product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1983
• Employees: 16
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: IVACC

Financial Performance

In 2025, Intervacc AB's revenue was 20.09 million, an increase of 70.42% compared to the previous year's 11.79 million. Losses were -80.82 million, 7.02% more than in 2024.